Fibrotic interstitial lung diseases (ILDs) are chronic and often progressive conditions resulting in substantial impact on morbidity, health-related quality of life (HRQoL), and health system costs. Ambulatory oxygen (AO) used during routine daily activities could lead to improved exercise performance, reduced symptoms and improved mobility in daily life. A UK prospective, multicentre, mixed method, randomised controlled crossover trial in patients with fibrotic ILD (AmbOx trial: NCT02286063), the first study on AO effects in daily life, reported improved HRQoL after 2 weeks of AO compared to no intervention, when measured by the King's Brief ILD (K-BILD) questionnaire [1–3]. Although AO is used in ILD, evidence supporting its health-economic impact is absent. Here, we evaluate the cost-effectiveness of AO in patients with ILD, using data collected alongside the AmbOx Trial. Ambulatory oxygen may be cost-effective in improving quality of life in fibrotic lung disease. To be more conclusive, we need to understand societal willingness to pay for quality of life improvements and whether improvements are sustained. http://bit.ly/2pAiBJi

中文翻译：

---

动态氧气在改善纤维化肺病患者生活质量方面的成本效益：来自 AmbOx 试验的初步证据

纤维化间质性肺病 (ILD) 是慢性且通常呈渐进性的疾病，会对发病率、健康相关生活质量 (HRQoL) 和卫生系统成本产生重大影响。在日常活动中使用动态氧气 (AO) 可以改善运动表现、减轻症状并改善日常生活中的活动能力。英国一项针对纤维化 ILD 患者的前瞻性、多中心、混合方法、随机对照交叉试验（AmbOx 试验：NCT02286063），这是第一项关于日常生活中 AO 影响的研究，报告称，与不干预相比，AO 2 周后 HRQoL 有所改善，当测量时通过 King's Brief ILD (K-BILD) 问卷 [1-3]。尽管 AO 用于 ILD，但缺乏支持其健康经济影响的证据。在这里，我们评估了 AO 在 ILD 患者中的成本效益，使用与 AmbOx 试验一起收集的数据。动态氧气在改善纤维化肺病的生活质量方面可能具有成本效益。为了更有说服力，我们需要了解社会愿意为改善生活质量付出代价，以及改善是否持续。http://bit.ly/2pAiBJi